| Literature DB >> 34946714 |
Alberto Hernandez-Leon1, Gabriel Fernando Moreno-Pérez1,2, Martha Martínez-Gordillo3, Eva Aguirre-Hernández4, María Guadalupe Valle-Dorado5, María Irene Díaz-Reval6, María Eva González-Trujano1, Francisco Pellicer1.
Abstract
The search for molecules that contribute to the relief of pain is a field of research in constant development. Lamiaceae is one of the most recognized families world-wide for its use in traditional medicine to treat diseases that include pain and inflammation. Mexico can be considered one of the most important centers of diversification, and due to the high endemism of this family, it is crucial for the in situ conservation of this family. Information about the most common genera and species found in this country and their uses in folk medicine are scarcely reported in the literature. After an extensive inspection in bibliographic databases, mainly Sciencedirect, Pubmed and Springer, almost 1200 articles describing aspects of Lamiaceae were found; however, 217 articles were selected because they recognize the Mexican genera and species with antinociceptive and/or anti-inflammatory potential to relieve pain, such as Salvia and Agastache. The bioactive constituents of these genera were mainly terpenes (volatile and non-volatile) and phenolic compounds such as flavonoids (glycosides and aglycone). The aim of this review is to analyze important aspects of Mexican genera of Lamiaceae, scarcely explored as a potential source of secondary metabolites responsible for the analgesic and anti-inflammatory properties of these species. In addition, we point out the possible mechanisms of action involved and the modulatory pathways investigated in different experimental models. As a result of this review, it is important to mention that scarce information has been reported regarding species of this family from Mexican genera. In fact, despite Calosphace being one of the largest subgenera of Salvia in the world, found mainly in Mexico, it has been barely investigated regarding its potential biological activities and recognized bioactive constituents. The scientific evidence regarding the different bioactive constituents found in species of Lamiaceae demonstrates that several species require further investigation in preclinical studies, and of course also in controlled clinical trials evaluating the efficacy and safety of these natural products to support their therapeutic potential in pain relief and/or inflammation, among other health conditions. Since Mexico is one of the most important centers of diversification, and due to the high endemism of species of this family, it is crucial their rescue, in situ conservation, and investigation of their health benefits.Entities:
Keywords: Agastache; Lamiaceae; Salvia; inflammation; nociception; pain
Mesh:
Substances:
Year: 2021 PMID: 34946714 PMCID: PMC8705283 DOI: 10.3390/molecules26247632
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Photographs of examples of Lamiaceae from Mexican Salvias (Calosphace subgenus). (A): S. circinnata Cav., (B): S. calderoniae Bedolla & Zamudio, (C): S. concolor Lamb. ex Benth., (D): S. divinorum Epling & Játiva, (E): S. involucrate Cav., (F): S. leucantha Cav., (G): S. karwinskii Benth., (H): S. mexicana L. (I): S. microphylla Kunth, (J): S. oaxacana Fernald, (K): S. pubescens Benth., (L): S. semiartrata, (M): S. tilantongensis J.G. González & Aguilar-Sant. and (N): S. wagneriana Zucc.
Figure 2(A) Worldwide distribution of plants of the Lamiaceae family [1] and (B) in Mexico (Modified from Martínez-Gordillo et al. [28]).
Figure 3Cladogram of Lamiaceae showing the monophyletic clades, where the different subfamilies are recognized. Subfamilies recognized by Olmstead: Ajugoideae, Lamioideae, Nepetoideae, Prostantheroideae, Scutellarioideae, Symphorematoideae, Tectonoideae, Callicarpoideae and Viticoideae (Modified from Li et al. [37]).
Lamiaceae species used in traditional medicine for pain, inflammation treatment and/or as antioxidants.
| Scientific | Medical Properties | Used | Preparation | ||
|---|---|---|---|---|---|
| Analgesic | Anti- | Antioxidant | |||
| X | Aerial parts | Hydroalcoholic extract | |||
| X | Leaves | Organic extracts | |||
| X | Aerial parts | Hydrodistillation, | |||
| X | Aerial parts | Infusion | |||
| X | Aerial parts | Maceration | |||
| X | Aerial parts | Infusion | |||
| X | Leaves | Methanol extract | |||
| X | Aerial parts | Hydroalcoholic extract | |||
| X | X | Aerial parts | Hydrodistillation | ||
| X | X | Aerial parts | Hydroalcoholic extract | ||
| X | X | X | Leaves, | Hydrodistillation, | |
| X | Aerial parts | Hydroalcoholic extract | |||
| X | X | Aerial parts | Organic extracts | ||
| X | X | Roots | Maceration | ||
| X | Leaves, | Tincture, | |||
| X | X | Leaves | Hydrodistillation | ||
| X | X | X | Aerial parts | Methanol extract | |
| X | Aerial parts | Methanol extract | |||
| X | X | Aerial parts | Hydrodistillation | ||
| X | X | Aerial parts | Methanol extract | ||
| X | Leaves | Decoction | |||
| X | X | Roots | Ethanol extract | ||
| X | Roots | Organic and aqueous extracts | |||
| X | X | Inflorescence | Ethanol extract | ||
| X | X | X | Aerial parts, | Maceration, | |
| X | X | X | Aerial parts, | Infusion, Decoction, | |
| X | Aerial parts | Organic extracts | |||
| X | Aerial parts | Organic extracts | |||
| X | X | Aerial parts, | Aqueous extract, | ||
| X | X | X | Aerial parts | Maceration | |
| X | Aerial parts | Maceration | |||
| X | X | Aerial parts | Organic extracts | ||
| X | Aerial parts | Hydroalcoholic extract | |||
| X | Aerial parts | Hydrodistillation | |||
| X | Leaves | Hydrodistillation | |||
| X | Leaves | Methanol extract | |||
| X | X | Leaves | Hydroalcoholic extract | ||
The scientific names were confirmed in The Plant List. Available online: http://www.theplantlist.org/ (Accessed on 2 December 2021).
Monoterpenes and sesquiterpenes present in Lamiaceae with biological activity and their molecular targets explored in pain and inflammation.
| Compound | Structure | Mechanism of Action | References |
|---|---|---|---|
| β-pinene |
| Decreased expression of IL-6, TNF-α, NO, iNOS and COX-2. | [ |
| Inhibition of COX-2 enzyme expression | [ | ||
| Limonene |
| Reduction in leukocyte infiltration and TNF-α levels. | [ |
| Decreased production of NO, PGE2 and Pro-inflammatory cytokines | [ | ||
| Linalool |
| Inhibition of pro-inflammatory interleukins and modulation of NMDA glutamatergic receptor. | [ |
| Reduction in oxidative stress and inflammation (NF-kB). | [ | ||
| Activation of opioid and muscarinic receptors | [ | ||
| Myrcene |
| Activation of opioid receptors and presynaptic α2 adrenoreceptor. | [ |
| Inhibition of IL-1β-induced NO production | [ | ||
| p-cymene |
| Reduced the production of pro-inflammatory cytokine TNF-α, the migration of leukocytes, and the release of NO. Activation of opioid receptors. | [ |
| Reduced the calcium current density. | [ | ||
| Thymol |
| Voltage-operated sodium channel blocker | [ |
| TRPA1 channel presynaptic activation | [ | ||
| Carvacrol |
| Inhibition of expression TNF-α, IL-1β, and IL-6 | [ |
| Modulation of opioid, vanilloid and glutamate systems | [ | ||
| α-humulene |
| Inhibition of pro-inflammatory cytokines (TNF-α and IL-1β) and PGE2 generation. | [ |
| β-caryophyllene |
| Cannabinoid receptor type 2 agonist. | [ |
| Agonist to opioid, benzodiazepine, 5HT1A receptors and NO. | [ |
Abbreviations: COX-2: Cyclooxygenase-2; IL-: Interleukin-; iNOS: Inducible nitric oxide synthase; LTB4: Leukotriene B4; MAPKs: Mitogen-activated protein kinase; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NMDA: N-methyl-D-aspartate receptor; NO: Nitric oxide; PGE2: Prostaglandin E2; TIMP-: Tissue inhibitors of metalloproteinase-; TNF-α: Tumor necrosis factor-alpha; TRPA1: Transient receptor potential cation channel, subfamily A, member 1.
Diterpenes and triterpenes present in Lamiaceae with biological activity and their molecular targets explored in pain and inflammation.
| Compound | Structure | Mechanism of Action | References |
|---|---|---|---|
| Tormentic acid |
| [ | |
| Increased activity of Superoxide dismutase, glutathione peroxidase and catalase. | [ | ||
| Andalusol |
| Inhibition of histamine | [ |
| Inhibition of iNOS expression by inactivation of NF-kB | [ | ||
| Tanshinone IIA |
| TLR2/NF-kB signaling pathway blocker | [ |
| Salvinorin A |
| KOR agonist. | [ |
| Inhibition of dopamine overflow mediated by KOR. | [ | ||
| α-amyrenone |
| PKC and PKA activity blocker. | [ |
| Antioxidant activity. | [ | ||
| β-amyrenone |
| Decreased levels of TNF-α and caspase 3 | [ |
| Ursolic acid |
| NO, PGE2 inhibitor. | [ |
| TRPV1 antagonist. | [ | ||
| Carnosol |
| Suppression of iNOS by down-regulation of NF-kB. | [ |
| Suppression of PGE2 synthesis by the inhibition of mPGES-1. | [ | ||
| Inhibition of the induction of COX-2 by blocking PKC signaling and thereby the binding of AP-1 to the CRE of the COX-2 promoter. | [ | ||
| Oleanolic acid |
| Opioid agonist. | [ |
| Opioid and 5-HT agonist. | [ | ||
| Betulinic acid |
| Reduction in TNF-α production. | [ |
| Reduction in the levels of COX-2, NO, TNF-α and IL-1β. | [ |
Abbreviations: 5HT: 5-hydroxytryptamine; 5HT1A: Serotonin 1A receptor; AP-1: activator protein 1; ATP: Adenosine triphosphate; CCL11: C-C motif chemokine 11; cGMP: Cyclic guanosine monophosphate; COX-2: Cyclooxygenase-2; CRE: cyclic AMP response element; GPx: glutathione peroxidase; GRd: glutathione reductase; IL-: Interleukin-; iNOS: Inducible nitric oxide synthase; KOR: κ-opioid receptor; LTB4: Leukotriene B4; MDA: Malondialdehyde; mPGES-1: Microsomal prostaglandin E synthase-1; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NO: Nitric oxide; PGE2: Prostaglandin E2; PKA: protein kinase A; PKC: protein kinase C; SOD: Superoxide dismutase; TLR2: Toll-like receptor 2; TNF-α: Tumor necrosis factor-alpha; TRPV1: Transient receptor potential cation channel subfamily V member 1.
Phenolic acids commonly found in Lamiaceae and their molecular targets explored in pain and inflammation.
| Compound | Structure | Mechanisms of Action | References |
|---|---|---|---|
| Rosmarinic acid |
| Antioxidant activity. | [ |
| Suppression of TNF-α, iNOs, apoptotic factors (Bax, caspases 3 and 9), Iba-1, TLR4 and GFAP levels. | [ | ||
| Gallic acid |
| ERK-Nrf2-Keap1-mediated antioxidant activity. | [ |
| Reduction in TBARS, total calcium, TNF-α, superoxide anion, and MPO activity levels; and decreased GSH level. | [ | ||
| TRPA1 antagonist. | [ | ||
| Chlorogenic acid |
| Inhibition of CD80/86 and Th1 cytokines. | [ |
| GABAA receptor agonist. | [ | ||
| Inhibition of NF-kB and JNK/AP-1 signaling pathways. | [ | ||
| Vanillin |
| Inhibition of protein and lipid oxidation processes. Increased activity of GSH, SOD, catalase.Suppresses the expression of TNF-α, IL-6, IL-1β and plasma AST and ALT enzymes. | [ |
| α2-adrenergic and opioid receptor agonist | [ | ||
| Caffeic acid |
| Reduction in the IκBα degradation and p65 phosphorylation in the NF-kB pathway. | [ |
| Inhibition of MPO, MDA and nitrite generation. | [ | ||
| Vanillic acid |
| α2-adrenoceptor agonist.5HT3 and 5HT1 receptor agonist Interaction with TRPV1, TRPA1 and TRPM8 receptors. | [ |
| Inhibition of oxidative stress, pro-inflammatory cytokine production, and NF-kB activation. | [ | ||
| Ferulic acid |
| The level/activity of elastase, lysosomal enzymes, nitric oxide, lipid peroxidation, and pro-inflammatory cytokines (TNF-α and IL-1β); and the mRNA expression of NLRP3 inflammasomes, caspase-1, pro-inflammatory cytokines, and NF-kB p65 were decreased. | [ |
| Inhibition of xanthine oxidase and COX-2 enzyme. | [ |
Abbreviations: 5HT: Serotonin; ALT: Alanine aminotransferase; AP-1: Activator protein 1; AST: Aspartate aminotransferase; Bax: Bcl-2-associated X protein; CD80/86: CD28 receptor binds to the B7; COX-2: Cyclooxygenase-2; ERK: Extracellular-signal-regulated kinase; GABAA: γ-aminobutyric acid type A receptor; GFAP: Glial fibrillary acidic protein; GSH: Glutathione; Iba-1: Ionized calcium-binding adapter molecule 1; IL-: Interleukin-; iNOS: Inducible nitric oxide synthase; IkBα: Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; JNK: c-Jun N-terminal kinase; Keap1: Kelch-like ECH-associated protein 1; MDA: Malondialdehyde; MPO: Myeloperoxidase; mRNA: Messenger Ribonucleic acid; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3: Family pyrin domain containing 3; NRf2: nuclear factor erythroid 2–related factor 2; p65: Nuclear factor NF-kappa-B p65 subunit; SOD: Superoxide dismutase; TBARS: Thiobarbituric acid reactive substances; Th1: T helper type 1; TLR4: Toll like receptor 4; TNF-α: Tumor necrosis factor-alpha; TNF-α: Tumor necrosis factor-alpha; TRPA1: Transient receptor potential ankyrin 1; TRPA1: Transient receptor potential cation channel, subfamily A, member 1; TRPM8: Transient receptor potential cation channel subfamily M (melastatin), member 8; TRPV1: Transient receptor potential cation channel subfamily V member 1.
Flavonoids commonly present in Lamiaceae and their molecular targets explored in pain and inflammation.
| Compound | Structure | Mechanism of Action | References |
|---|---|---|---|
| Pedalitin |
| Inhibitory effects against NO, TNF-α and IL-12. | [ |
| Rutin |
| Increased activity of GPx, GRd, CAT, SOD and GSH. | [ |
| Central modulation of the vlPAG descending circuit partly mediated by an opioidergic mechanism. | [ | ||
| Increased H2S level.Modulation of Nrf2 pathway. Caspase 3 and, NF-kB, TNF-α, IL-6 decreased.Increased sensory nerve conduction velocity. | [ | ||
| Apigenin |
| Increased expression levels of Nrf2 and HO-1.Inhibition of TNF-α, IL-1β, IL-6, MPO and MDA content. | [ |
| Inhibition of CD40, TNF-α and IL-6 | [ | ||
| Quercetin |
| Interaction with | [ |
| ROCs and VOCs Blocker Modulation of PGF2α pathway | [ | ||
| 5HT1A agonist | [ | ||
| Luteolin |
| Inhibition of IL-1β, TNF-α and histamine release. | [ |
| Decreased neutrophil infiltration.Inhibition of TNF-α, IL-1β, IL-6. | [ | ||
| Downregulation of TLR4/TRAF6/NF-kB pathway | [ | ||
| Inhibition of CD40, TNF-α and IL-6 | [ | ||
| Hesperidin |
| Modulation of D2, GABAA and opioid receptors. | [ |
| Agonist of opioid receptors. | [ | ||
| Modulation of TRPV1 receptor. | [ | ||
| Naringin |
| Inhibition of oxido-nitrosative strees, TNF-α, IL’s and NF-kB mRNA levels. | [ |
| Inhibition of PGE2, NO, IL-6 and TNF-α. | [ | ||
| Naringenin |
| Inhibition of NF-kB and activation of NO-Cyclic GMP-PKG-ATP sensitive K+ channel pathway | [ |
| Inhibition of IL-6, TNF-α and NO release, by interfering MAPK signal pathway and suppressing the activation of NF-kB. | [ |
Abbreviations: 5HT1A: Serotonin 1A receptor; ATP: Adenosine triphosphate; CAT: Catalase; CD40: Cluster of differentiation 40; GABA: γ aminobutyric acid; GMP: Cyclic guanosine monophosphate; GPx: glutathione peroxidase; GRd: glutathione; reductase; GSH: Glutathione; H2S: Hydrogen sulfide; HO-1: Heme oxygenase-1; IL-: Interleukin-; MAPK: Mitogen-activated protein kinase; MDA: Malondialdehyde; MPO: Myeloperoxidase; mRNA: Messenger Ribonucleic acid; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NO: Nitric oxide; Nrf2: Nuclear factor erythroid 2–related factor 2; PGE2: Prostaglandin E2; PGF2α: Prostaglandin F2α: PKG: cGMP-dependent protein kinase ROCs: Receptor-operated channels; SOD: Superoxide dismutase; TLR4: Toll-like receptor 4; TNF-α: Tumor necrosis factor-alpha; TRAF6: TNF receptor associated factor 6; TRPV1: Transient receptor potential cation channel subfamily V member 1; VOCs: Voltage-operated channels.